A Phase 1b Study of Mivebresib Alone or in Combination With Ruxolitinib or Navitoclax in Subjects With Myelofibrosis
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- 入组人数
- 1
- 试验地点
- 7
- 主要终点
- Percentage of Participants With Adverse Events
研究概览
简要总结
Myelofibrosis (MF) is a bone marrow illness that affects blood-forming tissues in the body. MF disturbs the body's normal production of blood cells, causing extensive scarring in the bone marrow. This leads to severe anemia, weakness, fatigue, and an enlarged spleen. The purpose of this study is to see how safe and tolerable mivebresib is, when given alone, and in combination with navitoclax or ruxolitinib, for adult participants with MF.
Mivebresib is an investigational drug being developed for the treatment of MF. The study has 4 segments - A, B, C, and D. In Segment A, the safe dosing regimen of mivebresib is identified, and then given alone as monotherapy. In Segment B, C, and D, combination therapies of mivebresib with either ruxolitinib or navitoclax are given. Adult participants with a diagnosis of MF will be enrolled. Around 130 participants will be enrolled in 60 sites worldwide.
In Segment A, participants will receive different doses and schedules of oral mivebresib tablet to identify a safe dosing regimen. Additional participants will be enrolled at the identified monotherapy dosing regimen. In Segment B, participants will receive oral ruxolitinib and mivebresib will be given as "add-on" therapy. In Segment C, participants will receive mivebresib and oral navitoclax. In Segment D, participants will receive mivebresib and ruxolitinib. Participants will receive treatment until disease progression or the participants are not able to tolerate the study drugs.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of treatment will be checked by medical assessments, blood and bone marrow tests, checking for side effects, and completing questionnaires.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Laboratory values indicative of adequate bone marrow, renal, and hepatic function meeting protocol criteria
- •Completion of the Myelofibrosis System Assessment Form (MFSAF) on at least 4 out of the 7 days prior to Day 1 with at least 2 symptoms with a score >=3 or a total score of >=
- •Documented diagnosis of intermediate or high-risk primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) or post-essential thrombocytopenia myelofibrosis (PET-MF) as defined by World Health Organization (WHO).
- •Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or
- •Intermediate - 2, or High-Risk disease as defined by the Dynamic International Prognostic Scoring System (For Segment A only, Intermediate - 1 with palpable splenomegaly >=5 centimeters [cm] below costal margin are also eligible).
- •Splenomegaly defined as spleen palpation measurement >= 5 centimeters (cm) below costal margin or spleen volume >= 450 cubic cms as assessed by Magnetic Resonance Imaging (MRI) or Computed Tomography (CT) scan (for Segments A and c, baseline spleen assessment must be obtained > 7 days after discontinuation of most recent Myelofibrosis (MF) therapy. If possible, this assessment should occur within 10 days of Cycle 1 Day 1).
- •Segment-Specific Prior Therapy Criteria:
- •Segment A:
- •-Prior exposure to one or more Janus Kinase Inhibitors (JAKi), the most recent of which was discontinued > 28 days prior to Cycle 1 Day
- •Segment B:
- •Currently receiving ruxolitinib; AND
- •Willingness to reduce dose (if on a higher dose); and on a stable dose for 14 days or longer prior to Cycle 1 Day 1; AND
- •At least one of the following criteria (a, b, or c):
- •>= 24 weeks duration of current ruxolitinib course, with evidence of disease that is resistant, refractory, or has lost response to ruxolitinib monotherapy;
- •< 24 weeks duration of current ruxolitinib course with documented disease progression as defined by any of the following:
- •Appearance of new splenomegaly that is palpable to at least 5 centimeters (cm) below the left costal margin (LCM), in participants with no evidence of splenomegaly prior to the initiation of ruxolitinib.
- •100% increase in the palpable distance below the LCM, in participants with measurable spleen distance 5 - 10 cm prior to the initiation of ruxolitinib.
- •50% increase in the palpable distance below the LCM, in participants with measurable spleen > 10 cm prior to the initiation of ruxolitinib.
- •A spleen volume increase >= 25% (as assessed by MRI or CT) in participants with a spleen volume assessment available prior to the initiation of ruxolitinib.
- •Prior treatment with ruxolitinib for >= 28 days complicated by any of the following:
- •Development of red blood cell transfusion requirement (at least 2 units/month for 2 months).
- •Grade >= 3 adverse events of neutropenia and/or anemia while on ruxolitinib treatment, with improvement or resolution upon dose reduction.
- •Segment C:
- •Prior exposure to one or more JAKi (the most recent of which was discontinued > 28 days prior to Cycle 1 Day 1), and are intolerant, resistant, refractory or lost response to teh JAKi.
排除标准
- •Segment-Specific Prior Therapy Criteria:
- •Segment A:
- •-Prior exposure to one or more Bromodomain and Extra Terminal (BET) inhibitors.
- •Segment B:
- •-Prior exposure to one or more BET inhibitors.
- •Segment C:
- •-Prior exposure to one or more BET inhibitors and/or any B-Cell Lymphoma 2 (BCL2) and/or B-Cell Lymphoma XL (BCLXL) inhibitor, including navitoclax.
- •Segment D:
- •Prior exposure to JAKi and/or any BET inhibitor.
研究组 & 干预措施
Segment A: Mivebresib Dose Identification and Optimization
Participants who have been previously treated with Janus Kinase inhibitor(s) (JAKi) and stopped such therapy, will receive different dosing regimens and schedules of mivebresib to identify the safe dosing regimen and schedule.
干预措施: Mivebresib (Drug)
Segment A: Mivebresib Monotherapy
Participants will receive the identified safe dosing regimen of mivebresib as monotherapy.
干预措施: Mivebresib (Drug)
Segment B: Ruxolitinib + Mivebresib "Add-on" Therapy
Participants whose disease (myelofibrosis) is inadequately controlled by ongoing ruxolitinib therapy will receive ruxolitinib and mivebresib as "add-on" therapy.
干预措施: Mivebresib (Drug)
Segment B: Ruxolitinib + Mivebresib "Add-on" Therapy
Participants whose disease (myelofibrosis) is inadequately controlled by ongoing ruxolitinib therapy will receive ruxolitinib and mivebresib as "add-on" therapy.
干预措施: Ruxolitinib (Drug)
Segment C: Mivebresib + Navitoclax
Participants who have previously been exposed to JAKi, and stopped such therapy, will receive mivebresib and navitoclax.
干预措施: Mivebresib (Drug)
Segment C: Mivebresib + Navitoclax
Participants who have previously been exposed to JAKi, and stopped such therapy, will receive mivebresib and navitoclax.
干预措施: Navitoclax (Drug)
Segment D: Mivebresib + Ruxolitinib
Participants who have never received JAKi will receive mivebresib and ruxolitinib.
干预措施: Mivebresib (Drug)
Segment D: Mivebresib + Ruxolitinib
Participants who have never received JAKi will receive mivebresib and ruxolitinib.
干预措施: Ruxolitinib (Drug)
结局指标
主要结局
Percentage of Participants With Adverse Events
时间窗: Up To Approximately 1 year from start of study
An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with the treatment. The investigator assesses the relationship of each event to the use of study drug.
次要结局
- Apparent Clearance (CL/F) of Mivebresib(Up To Week 12)
- Percentage of Participants who Achieve Spleen Volume Reduction of 35% or Greater (SVR35)(Up To Week 24)
- Area Under Concentration vs Time Curve (AUC) of Mivebresib(Up To Week 12)
- Accumulation Ratio of Mivebresib(Up To Week 12)
- Maximum Observed Plasma Concentration (Cmax) of Navitoclax(Up To Week 12)
- Time to Cmax (Tmax) of Ruxolitinib(Up To Week 12)
- Maximum Observed Plasma Concentration (Cmax) of Mivebresib(Up To Week 12)
- Time to Cmax (Tmax) of Mivebresib(Up To Week 12)
- Percentage of Participants With >= 50% Reduction in Total Symptom Score (TSS)(Week 24)
- Half-Life (t1/2) of Mivebresib(Up To Week 12)
- Time to Cmax (Tmax) of Navitoclax(Up To Week 12)
- Area Under Concentration vs Time Curve (AUC) of Navitoclax(Up To Week 12)
- Objective Response Rate (ORR)(Week 24)
- Maximum Observed Plasma Concentration (Cmax) of Ruxolitinib(Up To Week 12)
- Area Under Concentration vs Time Curve (AUC) of Ruxolitinib(Up To Week 12)
- Apparent Volume of Distribution (Vd/F) of Mivebresib(Up To Week 12)